CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant

A phase I open-label study of escalating-dose oral cyclophosphamide (CTX), docetaxel (D), zoledronic acid (ZA), and high-dose calcitriol (HDC) for castration-resistant prostate cancer (CRPC).

10.1200/jco.2010.28.15_suppl.e15079 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e15079-e15079

Author(s):

C. E. Souza ◽

D. A. Bastos ◽

D. F. Jardim ◽

S. C. Martins ◽

R. Laporti ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

High Dose ◽

Oral Cyclophosphamide ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Dose Oral

Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).

10.1200/jco.2015.33.15_suppl.5040 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5040-5040 ◽

Cited By ~ 2

Author(s):

David I. Quinn ◽

Charles G. Drake ◽

Robert Dreicer ◽

Emmanuel S. Antonarakis ◽

Neal D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Immune Response ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Randomized Phase 2

A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.

10.1200/jco.2015.33.15_suppl.tps5072 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5072-TPS5072 ◽

Cited By ~ 14

Author(s):

Robert B. Montgomery ◽

Emmanuel S. Antonarakis ◽

Maha Hussain ◽

Karim Fizazi ◽

Anthony M. Joshua ◽

...

Keyword(s):

Prostate Cancer ◽

Antitumor Activity ◽

Phase 1 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Terminal Domain ◽

Castration Resistant

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).

10.1200/jco.2014.32.15_suppl.e16071 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16071-e16071 ◽

Cited By ~ 4

Author(s):

David I. Quinn ◽

Daniel Peter Petrylak ◽

Christopher Michael Pieczonka ◽

Andrew Sandler ◽

Todd DeVries ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Randomized Phase Ii

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p145 ◽

2015 ◽

Vol 3 (Suppl 2) ◽

pp. P145 ◽

Cited By ~ 1

Author(s):

Charles G Drake ◽

David Quinn ◽

Robert Dreicer ◽

Emmanuel Antonarakis ◽

Neal Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Immune Response ◽

Phase Ii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Randomized Phase Ii

A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone

European Urology Supplements ◽

10.1016/s1569-9056(16)30439-0 ◽

2016 ◽

Vol 15 (13) ◽

pp. e1645-e1646 ◽

Cited By ~ 1

Author(s):

G. Attard ◽

R. Montgomery ◽

U. Vaishampayan ◽

M. Gordon ◽

D. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Antitumor Activity ◽

Phase 1 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Terminal Domain ◽

Castration Resistant

Stride, a Randomized, Phase 2, Open-Label Study of Sipuleucel-T with Concurrent Vs Sequential Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Annals of Oncology ◽

10.1093/annonc/mdu336.22 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

D.P. Petrylak ◽

D.I. Quinn ◽

R. Dreicer ◽

E.S. Antonarakis ◽

N.D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Randomized Phase 2

Re-treatment with radium-223: An international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases.

10.1200/jco.2016.34.15_suppl.5074 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5074-5074

Author(s):

A. Oliver Sartor ◽

Daniel Heinrich ◽

Neil Mariados ◽

María José Méndez-Vidal ◽

Daniel Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Radium 223

A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct04179864 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Phase 1B

Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdw372.36 ◽

2016 ◽

Vol 27 ◽

pp. vi255

Author(s):

O. Sartor ◽

D. Heinrich ◽

N. Mariados ◽

M.J. Méndez Vidal ◽

D. Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Castration Resistant ◽

Radium 223